Abstract
Cervical cancer is a leading cause of cancer-related deaths among women in India. Human papillomavirus (HPV) infection is the causative agent of cervical cancer; and infection with the high-risk genotypes, predominantly HPV16 and 18, is the biggest risk factor. Vaccines targeting HPV16 and 18 have been found to confer protection in large-scale clinical trials. HPV genotyping has traditionally been carried out to screen the population “at risk” using indirect methods based on polymerase chain reaction (PCR) using consensus primers combined with various DNA hybridization techniques, and often followed by the sequencing of candidate products. Recently, a high-throughput and direct method based on DNA sequencing has been described for HPV genotyping using multiplex pyrosequencing. We present a pilot study on HPV genotyping of cervical cancer and non-malignant cervical samples using multiplex pyrosequencing. Using genomic DNA from cell lines, cervical biopsies, surgical tissues or formalin-fixed, paraffin-embedded tissue samples, we could successfully resolve 6 different HPV types out of the 7 tested, with their prevalence found to be in agreement with earlier reports. We also resolved coinfections with two different HPV types in several samples. An HPV16 genotype with a specific and recurrent sequence variation was observed in 8 cancer samples and one non-malignant sample. We find this technique eminently suited for high-throughput applications, which can be easily extended to large sample cohorts to determine a robust benchmark for HPV genotypes prevalent in India.
Similar content being viewed by others
References
Bosch F X, Lorincz A, Munoz N, Meijer C J and Shah K V 2002 The causal relation between human papillomavirus and cervical cancer; J. Clin. Pathol. 55 244–265
Choi Y D, Jung W W, Nam J H, Choi H S and Park C S 2005 Detection of HPV genotypes in cervical lesions by the HPV DNA chip and sequencing; Gynecol. Oncol. 98 369–375
Clifford G M, Smith J S, Plummer M, Munoz N and Franceschi S 2003 Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis; Br. J. Cancer 88 63–73
Cope J U, Hildesheim A, Schiffman M H, Manos M M, Lorincz A T, Burk R K, Glass A G, Greer C et al 1997 Comparison of the hybrid capture tube test and PCr for detection of human papillomavirus DNA in cervical specimens; J. Clin. Microbiol. 35 2262–2265
Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H and Franco E 2002 Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples; J. Clin. Microbiol. 40 902–907
de Roda Husman A M, Walboomers J M, van den Brule A J, Meijer C J and Snijders P J 1995 The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR; J. Gen. Virol. 76 (Pt 4) 1057–1062
Elahi E and Ronaghi M 2004 Pyrosequencing: a tool for DNA sequencing analysis; Methods Mol. Biol. 255 211–219
Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders P J, Munoz N, Meijer C J and Herrero R 2003 Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study; Int. J. Cancer 107 127–133
Franceschi S, Rajkumar R, Snijders P J, Arslan A, Mahe C, Plummer M, Sankaranarayanan R, Cherian J, Meijer C J and Weiderpass E 2005 Papillomavirus infection in rural women in southern India; Br. J. Cancer 92 601–606
Frazer I H 2004 Prevention of cervical cancer through papillomavirus vaccination; Nat. Rev. Immunol. 4 46–54
Gharizadeh B, Kalantari M, Garcia C A, Johansson B and Nyren P 2001 Typing of human papillomavirus by pyrosequencing; Lab. Invest. 81 673–679
Gharizadeh B, Ghaderi M, Donnelly D, Amini B, Wallin KL and Nyren P 2003 Multiple-primer DNA sequencing method; Electrophoresis 24 1145–1151
Gharizadeh B, Oggionni M, Zheng B, Akom E, Pourmand N, Ahmadian A, Wallin K L and Nyren P 2005 Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology; J. Mol. Diagn. 7 198–205
Gharizadeh B, Zheng B, Akhras M, Ghaderi M, Jejelowo O, Strander B, Nyren P, Wallin K L and Pourmand N 2006 Sentinel-base DNA genotyping using multiple sequencing primers for high-risk human papillomaviruses; Mol. Cell Probes 20 230–238
Harper D M, Franco E L, Wheeler C M, Moscicki A B, Romanowski B, Roteli-Martins C M, Jenkins D, Schuind A, Costa Clemens S A and Dubin G 2006 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial; Lancet 367 1247–1255
Jacobs M V, de Roda Husman A M, van den Brule A J, Snijders P J, Meijer C J and Walboomers J M 1995 Group-specific differentiation between high-and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes; J. Clin. Microbiol. 33 901–905
Klaassen C H, Prinsen C F, de Valk H A, Horrevorts A M, Jeunink M A and Thunnissen F B 2004 DNA microarray format for detection and subtyping of human papillomavirus; J. Clin. Microbiol. 42 2152–2160
Legood R, Gray A M, Mahe C, Wolstenholme J, Jayanth K, Nene B M, Shashtri S S, Malvi S G, Muwonge R, Budukh A and Sankaranarayanan R 2005 Screening for cervical cancer in India: how much will it cost? A trial based analysis of the cost per case detected; Int. J. Cancer 117 981–987
Lie A K, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M and Thoresen S 2005 DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia; Gynecol. Oncol. 97 908–915
Menon M M, Simha M R and Doctor V M 1995 Detection of human papillomavirus (HPV) types in precancerous and cancerous lesions of cervix in Indian women: a preliminary report; Indian J. Cancer 32 154–159
Moscicki A B, Schiffman M, Kjaer S and Villa L L 2006 Chapter 5: updating the natural history of HPV and anogenital cancer; Vaccine 24(Suppl 3) S42–S51
Munirajan A K, Kannan K, Bhuvarahamurthy V, Ishida I, Fujinaga K, Tsuchida N and Shanmugam G 1998 The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India; Gynecol. Oncol. 69 205–209
Munoz N, Bosch F X, de Sanjose S, Herrero R, Castellsague X, Shah K V, Snijders P J and Meijer CJ 2003 Epidemiologic classification of human papillomavirus types associated with cervical cancer; N. Engl. J. Med. 348 518–527
Nelson J H, Hawkins G A, Edlund K, Dvander M, Kjellberg L, Wadell G, Dillner J, Gerasimova T et al 2000 A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples; J. Clin. Microbiol. 38 688–695
Pretet J L, Jacquard A C, Carcopino X, Charlot J F, Bouhour D, Kantelip B, Soubeyrand B, Leocmach Y, Mougin C and Riethmuller D 2008a Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study; Int. J. Cancer 122 424–427
Pretet J L, Jacquard A C, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, Leocmach Y, Mougin C and Riethmuller D 2008b Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study; Int. J. Cancer 122 428–432
Roden R and Wu T C 2006 How will HPV vaccines affect cervical cancer?; Nat. Rev. Cancer 6 753–763
Ronaghi M 2001 Pyrosequencing sheds light on DNA sequencing; Genome Res. 11 3–11
Sankaranarayanan R, Chatterji R, Shastri S S, Wesly R S, Basu P, Mahe C, Mowonge R, Sgigneurin D, et al 2004 Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India; Int. J. Cancer 112 341–347
Sankaranarayanan R, Nene B M, Dinshaw K A, Mahe C, Jayanth K, Shastri S S, Malvi S G, Chinoy R, et al 2005 A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India; Int. J. Cancer 116 617–623
Schmiedeskamp M R and Kockler D R 2006 Human papillomavirus vaccines; Ann. Pharmacother. 40 1344–1352
Shastri S S, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, Kane S, Kelkar R et al 2005 Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India; Bull. World Health Organ. 83 186–194
Smits H L, Bollen L J, Tjong A H S P, Vonk J, Van Der Velden J, Ten Kate F J, Kaan J A, Mol B W and Ter Schegget J 1995 Intermethod variation in detection of human papillomavirus DNA in cervical smears; J. Clin. Microbiol. 33 2631–2636
Sowjanya A P, Jain M, Poli U R, Padma S, Das M, Shah K V, Rao B N, Devi R R, Gravitt P E and Ramakrishna G 2005 Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India; BMC Infect. Dis. 5 116
Trottier H and Franco EL 2006 The epidemiology of genital human papillomavirus infection; Vaccine (Suppl 1) 24 S1–S15
Unger E R 2000 In situ diagnosis of human papillomaviruses; Clin. Lab. Med. 20 289–301, vi
van den Brule A J, Pol R, Fransen-Daalmeijer N, Schouls L M, Meijer C J and Snijders P J 2002 GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes; J. Clin. Microbiol. 40 779–787
Ylitalo N, Bergstrom T and Gyllensten U 1995 Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization; J. Clin. Microbiol. 33 1822–1828
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Travasso, C.M., Anand, M., Samarth, M. et al. Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India. J Biosci 33, 73–80 (2008). https://doi.org/10.1007/s12038-008-0023-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12038-008-0023-x